Clinical trials: PSP
Progressive Supranuclear Palsy, Cognitive Impairment
Neuropsychological Evaluation for Early Diagnosis of PSP
The aim of this study is to better understand the nature of the cognitive decline in Progressive Supranuclear Palsy, the time of its development and the relation with the other cardinal features of the disease.
- Trial name
- NCT03478124
- Testing
- Cognitive evaluation
- Volunteers
- 112 people
- Sponsor
- Ospedale Generale Di Zona Moriggia-Pelascini
Progressive Supranuclear Palsy, PSP
AMX0035 and Progressive Supranuclear Palsy
A35-009 (ORION) is a Phase 2b/3 trial to evaluate the efficacy and safety of AMX0035 in participants with Progressive Supranuclear Palsy (PSP), consisting of randomized, double blind placebo controlled phases, followed by an…
- Conditions
- Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
- Trial name
- ORION (NCT06122662)
- Testing
- AMX0035
- Where
- 62 sites in United States, France and 3 more
- Volunteers
- 139 people
- Sponsor
- Amylyx Pharmaceuticals Inc.
Thoracic Surgical Procedures
Thoracoscopic Bullectomy Versus Thoracoscopic Bullectomy With Pleurodesis in Primary Spontaneous Pneumothorax
The exact pathogenesis of PSP is controversial. A few theories has been proposed contributing to the pathogenesity of the PSP as emphysematous like changes (ELCs) which lead to the formation and rupture of the lung bullae or…
- Trial name
- NCT03943069
- Testing
- Thoracoscopic bullectomy alone, Thoracoscopic bullectomy with pleurodesis
- Where
- Saudi Arabia
- Volunteers
- 232 people
- Sponsor
- Imam Abdulrahman Bin Faisal University
Progressive Supranuclear Palsy
Image Characteristic and Longitudinal Follow up of 18F-PMPBB3 (APN-1607) PET for Progressive Supranuclear Palsy
The study will enroll 20 PSP and 8 normal subjects with complete neurological examination, 18F-PMPBB3 (APN-1607) PET and MRI assessment.
- Trial name
- NCT04541836
- Testing
- 18F-PMPBB3
- Where
- Taiwan
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Tauopathies
Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A
The current protocol is to determine the biodistribution, metabolism, excretion and brain uptake of 18F-JSS20-183A. The goal of this radiotracer is to quantify 4Repeat Tau (4Rtau) protein that is abnormally deposited in the brain…
- Trial name
- NCT06932809
- Testing
- 18F-JSS20-183A PET, Brain MRI, Amyloid PET
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- University of Pennsylvania
Systemic Sclerosis
Catestatin as a Novel Biomarker for Cardiovascular and Microvascular Involvement in Systemic Sclerosis
This study investigates the relationship between serum catestatin levels and systemic sclerosis (SSc), with a focus on cardiovascular involvement and microvascular alterations, to determine catestatin's potential as a biomarker…
- Trial name
- NCT07209644
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Assiut University
Parkinson Disease, Osteoporosis
Trial of Parkinson's And Zoledronic Acid
This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and…
- Conditions
- Parkinson Disease, Osteoporosis, Parkinsonism, Parkinson's Disease and Parkinsonism
- Trial name
- TOPAZ (NCT03924414)
- Testing
- Zoledronic Acid 5Mg/Bag 100Ml Inj
- Where
- 77 sites in United States
- Volunteers
- 2,721 people
- Sponsor
- California Pacific Medical Center Research Institute
Frontotemporal Degeneration (FTD), ALS (Amyotrophic Lateral Sclerosis)
Biofluid Research on Age-Related or Inherited Neurodegeneration
The aim of this study is to contribute to and continue to sustain a repository of blood samples, nucleic acid (DNA and/or RNA) samples, family history information, and other demographic information from individuals with…
- Conditions
- Frontotemporal Degeneration (FTD), ALS (Amyotrophic Lateral Sclerosis), Primary Progressive Aphasia (PPA), Familial Frontotemporal Lobar Degeneration (fFTLD)
- Trial name
- BRAIN (NCT07798700)
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Progressive Supranuclear Palsy, Corticobasal Degeneration
Wellness in PSP and CBD
The goal of this interventional study is to evaluate the feasiblity and effectiveness of a multimodal lifestyle program for individuals living with Progressive Supranuclear Palsy or Corticobasal Deneration.
- Trial name
- NCT07844655
- Testing
- Exercise and Peer Support
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Silke Cresswell
Sepsis, Sepsis Bacterial
Analytical Validation of the abioSCOPE Device With the IVD CAPSULE PSP Test: Comparison of PSP Values Measured With Venous Whole Blood and Those Measured With Arterial Whole Blood.
Abionic has developed a targeted, rapid test for pancreatic stone protein (PSP) in human K2-EDTA venous whole blood using the abioSCOPE instrument.
- Trial name
- NCT05627076
- Testing
- Blood Sampling
- Where
- France
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Abionic SA
Alzheimer's Disease, Cortical Basal Syndrome
18F-PM-PBB3 PET Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal Controls
This is an open-label study to evaluate the performance of a novel tau imaging ligand in up to 36 subjects (12 AD, 3 FTD, 3 PSP, 3 CBS, 3 VCI and 12 HV).
- Conditions
- Alzheimer's Disease, Cortical Basal Syndrome, Frontotemporal Dementia, Progressive Supranuclear Palsy
- Trial name
- NCT03625128
- Testing
- F-18
- Where
- Taiwan
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Progressive Supranuclear Palsy
Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy (Depakine)
Progressive Supranuclear Palsy (PSP) is a relentlessly progressive neurodegenerative disorder, clinically characterized by parkinsonism with prominent axial involvement and postural instability, bulbar symptoms, supranuclear…
- Trial name
- NCT00385710
- Testing
- valproic acid
- Where
- 4 sites in France
- Volunteers
- 28 people
- Sponsor
- Nantes University Hospital
Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
This Phase III study is intended to evaluate the efficacy and safety of NIO752 in participants with Progressive Supranuclear Palsy (PSP).
- Trial name
- NCT07498426
- Testing
- NIO752
- Where
- 64 sites in United States, Australia and 10 more
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
Schizophrenia
Evaluation of the Functional Remission Occurrence and Predictive Factors in Schizophrenia
In a population of patients suffering from schizophrenia being treated for an episode of clinical destabilization and followed for a period of twelve months, the main objective is to evaluate the proportion of patients achieving…
- Trial name
- NCT02874560
- Where
- France
- Volunteers
- 364 people
- Sponsor
- Janssen-Cilag Ltd.
Progressive Supranuclear Palsy
The MOTIVE-PSP Initiative (Progressive Supranuclear Palsy)
Progressive Supranuclear Palsy (PSP) is a rapidly progressive neurodegenerative disease characterized by falls and oculomotor disturbances.
- Trial name
- NCT04691635
- Testing
- evaluation of movements with sensors
- Where
- 3 sites in Italy
- Volunteers
- 165 people
- Sponsor
- University of Salerno